Evaluating Safety and Effectiveness of High-Dose Stereotactic Radiotherapy for Thoracic Cancers Based on Tumor Location

What this Trial Is About

Researchers are studying the use of stereotactic body radiation therapy SBRT to treat malignant tumors in the chest area, including thoracic cancer. SBRT can deliver high doses of radiation precisely to the tumor while minimizing damage to nearby healthy organs. The study aims to understand the safety and effectiveness of SBRT in different chest regions, categorized as chest wall type, peripheral type, central type, and ultral-central type, because different chest organs tolerate radiation differently. Participants receive SBRT with doses ranging from 48 to 60 Gy over 4 to 10 treatment sessions, depending on the tumor location. The study groups are divided by tumor position relative to the chest wall, bronchial tree, and mediastinal structures. This approach helps explore how radiation dose and side effects vary by tumor site. During the study, researchers will monitor participants from the start of treatment up to 2 years afterward. They will assess local progression-free survival, radiation-related side effects, and overall survival. Participants will undergo evaluations to measure tumor control and treatment safety. The total study duration includes follow-up to track long-term outcomes and side effects.

Safety and Efficacy of SBRT in the Treatment of Thoracic Malignant Tumors at Different Sites